# Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

> **NCT02626507** · PHASE1 · UNKNOWN · sponsor: **Hoffman Oncology** · enrollment: 18 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Gedatolisib
- **DRUG:** Faslodex
- **DRUG:** Palbociclib
- **DRUG:** Zoladex

## Key facts

- **NCT ID:** NCT02626507
- **Lead sponsor:** Hoffman Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2022-02-15
- **Final completion:** 2022-03-15
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2022-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02626507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02626507, "Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02626507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*